Colgate-Palmolive (CL): Revisiting Valuation After This Year’s 14% Share Price Slide

Simply Wall St

Colgate-Palmolive (CL) has quietly slipped about 14 % this year, even as its underlying business keeps grinding forward with steady revenue and profit growth. That disconnect is exactly what makes the stock interesting now.

See our latest analysis for Colgate-Palmolive.

Despite the recent pullback, including a roughly 9% 90 day share price return and a 14% year to date share price decline to about $77.60, Colgate Palmolive still shows a positive three year total shareholder return. This suggests that long term momentum has cooled rather than disappeared.

If Colgate Palmolive’s reset has you reassessing the staples space, it could be a good moment to broaden your watchlist and explore fast growing stocks with high insider ownership

So with earnings still growing, shares trading below analyst targets and a sizeable intrinsic value gap implied, is Colgate Palmolive quietly slipping into undervalued territory, or are markets already pricing in its next leg of growth?

Most Popular Narrative Narrative: 11% Undervalued

With Colgate Palmolive last closing at $77.60 against a narrative fair value of $87.21, the current setup leans toward a discounted price, but the story hinges on how its long term earnings path is modeled.

Productivity and restructuring initiatives ($200 to $300 million over three years) are designed to free up resources for innovation, digital, and R&D investments, enabling incremental margin expansion and additional reinvestment for growth.

Read the complete narrative.

Want to see the full playbook behind that margin boost, the earnings climb it implies, and the richer multiple it relies on? Read the complete narrative to uncover the specific growth, profitability, and valuation assumptions that power this fair value call.

Result: Fair Value of $87.21 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent raw material cost pressures and prolonged consumer caution in key markets could squeeze margins and derail the gradual earnings recovery implied in this narrative.

Find out about the key risks to this Colgate-Palmolive narrative.

Another Take On Valuation

Looked at through a simple earnings lens, Colgate Palmolive screens quite differently. Its current price to earnings ratio of 21.5 times sits above the global household products average of 17.5 times and above a fair ratio of 19.5 times, suggesting less obvious bargain and more valuation risk if growth disappoints.

See what the numbers say about this price — find out in our valuation breakdown.

NYSE:CL PE Ratio as at Dec 2025

Build Your Own Colgate-Palmolive Narrative

If this perspective does not quite align with your own or you prefer to dive into the numbers yourself, you can craft a personalized thesis in minutes: Do it your way

A great starting point for your Colgate-Palmolive research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more high conviction investment ideas?

Before you move on, lock in a few fresh opportunities by using the Simply Wall Street Screener to uncover compelling stocks that match your strategy and risk profile.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Colgate-Palmolive might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com